CommonHealth lands vet to run patient, interactive

Share this article:
E-marketing veteran Meg Columbia-Walsh has joined WPP-held CommonHealth as managing partner and president.

In her new role, Columbia-Walsh assumes responsibility for CommonHealth's consumer, patient and interactive business, she told MM&M.

“The consumer industry has gone through a lot of change,” said Columbia-Walsh. “We went from being a healthcare-only

discipline to a direct-to-consumer discipline based on the packaged-goods model. Old tactics are not going to work. We really need to harness and build strategic insight into positioning that can be truly articulated into multiple channels. I think that is really the goal moving forward.”

Describing Columbia-Walsh as a force in the industry, CommonHealth CEO Matt Giegerich said, “We're absolutely convinced she will help drive CommonHealth's growth.”

In her 20-year career, Columbia-Walsh has served as managing director of healthcare and technology at Faith Popcorn's Brain Reserve; was partner/VP at Cap Gemini Ernst & Young; founded online healthcare advertising agency HealthTech Digital Communications; founded CBS Healthwatch; and was CEO of Oncology.com.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...